Clinical Trial Update: Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating an individualized neoantigen cancer vaccine in combination with an immune checkpoint blocker for colorectal cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Immune checkpoint inhibitor
• Neoantigen cancer vaccine (individualized)

Snippet

Sponsor: Gritstone bio, Inc. | Conditions: Colonic Neoplasms, Colorectal Neoplasms | Phase 2 | Status: WITHDRAWN